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Abstract
Objectives To assess the potential influence of systemic antibiotic administration on the healing of periodontal intrabony defects
treated with deproteinized bovine bone mineral (DBBM) and collagen membrane.
Materials and methods Forty-one intrabony defects were treated by means of DBBM and collagen membrane (GTR).
Postoperatively, the patients received either systemic antibiotics (i.e., 1 g of amoxicillin, twice daily for 7 days) (test) or no
antibiotics (control). Clinical attachment level (CAL), probing depth (PD), and gingival recession (GR) were measured at
baseline and at 1 year following regenerative surgery. The depth of the intrabony component (INTRA DD) and its width
(INTRA DW) were measured during surgery and after 1 year at reentry. The depth (RxD) and width (RxW) of the intrabony
defects were evaluated radiographically at baseline and at 1 year.
Results No adverse events were observed in any of the two groups throughout the entire study period. In the test group, mean
CAL changed from 8.7 ± 1.4 mm at baseline to 5.0 ± 1.7 mm at 1 year (p < 0.0001), while PD decreased from 7.8 ± 1.5 mm at
baseline to 4.0 ± 0.9 mm at 1 year (p < 0.0001). In the control group, mean CAL changed from 8.6 ± 1.9 mm to 5.9 ± 1.6 mm
(p < 0.001) and mean PD improved from 7.4 ± 1.3 mm to 4.1 ± 1.3 mm (p < 0.001). Mean CAL gain measured 3.6 ± 1.6 mm in
the test and 2.7 ± 1.6 mm in the control group, respectively. Defect fill (i.e., INTRA DD gain) at re-entry measured 3.7 ± 1.8 mm
in the test and 2.7 ± 2.1 mm in the control group. A CAL gain of ≥ 3 mmwas measured in 76% of the defects in the test group and
in 40% of the defects in the control group, respectively. In both groups, all evaluated clinical and radiographic parameters
improved statistically significantly compared with baseline, but no statistically significant differences were found between the
two groups.
Conclusions Within their limits, the present study has failed to show any substantial added clinical benefits following the
postoperative administration of amoxicillin in conjunction with regenerative periodontal surgery using DBBM and GTR.
Clinical relevance The post-surgically administration of systemic antibiotics does not seem to be necessary following regener-
ative periodontal surgery.
Keywords Periodontal intrabony defects . Periodontal regeneration . Guided tissue regeneration . Deproteinized bovine bone
mineral . Systemic antibiotics
Introduction
The goal of regenerative periodontal surgery is to reconstruct
the tooth’s supporting tissues (i.e., periodontal ligament, root
cementum, and bone) that have been lost following inflamma-
tory periodontal disease or trauma [1, 2]. A plethora of differ-
ent treatment modalities including tissue preservation flaps in
conjunction with bone grafts/bone substitutes, guided tissue
regeneration (GTR), enamel matrix derivative (EMD), growth
factors, or various combination thereof, have been widely
employed in order to facilitate periodontal regeneration in
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intrabony and furcation defects [1–5]. Substantial evidence
from long-term clinical studies indicates that regenerative
periodontal surgery represents a realistic treatment modality
for improving the prognosis of periodontally compromised
teeth, thus contributing to tooth maintenance [6–9]. The com-
bination of a deproteinized bovine bone mineral (DBBM) and
collagen membrane (GTR) is a widely used and well-
documented treatment modality in regenerative periodontal
surgery [1, 10–12].
Inmost clinical scenarios, systemic antibiotics are routinely
given following regenerative periodontal surgery to reduce
postoperative complications caused by bacterial infections.
However, the data from controlled clinical studies evaluating
the potential influence of a postoperative administration of
systemic antibiotics following regenerative periodontal sur-
gery is still limited [13, 14]. However, the use of regenerative
biomaterials such as bone grafts and membranes may increase
the risk of postoperative complications such as membrane
exposure and subsequent bacterial colonization, thus jeopar-
dizing the clinical outcomes. Therefore, in order to minimize
these potential complications, systemic antibiotics are fre-
quently administered after regenerative periodontal surgery
involving the use of bone grafts and barrier membranes [15].
However, at present, there are virtually no data from random-
ized controlled clinical studies evaluating the use of systemic
antibiotics following regenerative periodontal surgery by
means of DBBM and GTR.
Therefore, the aim of the present study was to evaluate the
potential effect of systemic antibiotics administration follow-
ing regenerative periodontal surgery with DBBM and GTR.
Material and methods
Study sample and experimental design
The study was planned as a randomized, prospective, con-
trolled clinical trial with reentry procedures. Prior to patient
recruitment, the study protocol was approved by the local
ethical committee (R-I-002-302-2013) in accordance with
the Helsinki Declaration of 1975 as revised in 2000.
Following screening and detailed explanation about the
aim and scope of the study, all patients participating in the
study have signed the inform consent. The informed con-
sent contained also detailed information about the planned
re-entry procedures at the 12-month evaluation period and
could freely agree or not with the possibility of a re-entry
surgery.
A total of 41 patients diagnosed with stage III periodontitis
[16] and having at least one intrabony defect that were referred
for periodontal therapy to the Department of Periodontal and
Oral Mucosa Diseases, Medical University of Bialystok were
included in the study.
The criteria for inclusion were:
& Presence of at least one intrabony defect with a probing
depth (PD) ≥ 6 mm associated with an intrabony compo-
nent exhibiting a radiographic depth (RxD) of ≥ 3 mm and
a width (RxW) of ≥ 2 mm as measured on the intraoral
radiographs
& At least 18 years of age
& No allergic reaction to amoxicillin or other antibiotics be-
longing to the penicillin family
& Good level of oral hygiene evidenced by full mouth
plaque scores (FMPS < 20%) [17], and full mouth bleed-
ing scores (FMBS < 20%) [18]
& Non smoking
The exclusion criteria were:
& Intake of antibiotics within at least 3 months prior to the
study
& Systemic diseases such as diabetes, immunodeficiencies
and others that may affect wound healing
& Pregnancy and breastfeeding
The patients were distributed in the test and control groups
using random allocation by means of a computer program
(written for this purpose by RM). Patient’s allocation is
depicted in Fig. 1.
Surgical procedure
In order to standardize the surgical technique, the same
experienced surgeon (MP) performed all interventions un-
der local anesthesia (Ubistesin forte, 3M ESPE, Seefeld,
Germany). The surgeon has only met the patient immedi-
ately before regenerative surgery and at the reentry surgery
(in cases where re-entry was performed). The surgical tech-
nique consisted of intrasulcular incisions and preparation
of mucoperiosteal flaps buccally and lingually according to
the principles of papilla preservation technique [3, 4].
Vertical incisions were only made if needed to obtain eas-
ier access to the defect. Subsequently, the granulation tis-
sue was removed and the root surfaces were thoroughly
scaled and planed by means of hand instruments (i.e.,
Gracey currettes, Hu-Friedy, Chicago, IL, USA) and ultra-
sonic scalers (EMS Piezon Tip PS, EMS, Nyon,
Switzerland).
Following site preparation, the defects were filled with
the DBBM (Cerabone®, botiss biomaterials GmbH,
Zossen, Germany) and covered with a collagen membrane
(GTR) (Collprotect®, botiss biomaterials GmbH, Zossen,
Germany). Once the membrane was in place, the
mucoperiosteal flap was coronally displaced and stabilized
over the defect by means of vertical modified mattress
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sutures, while the remaining papillae and vertical incisions
were closed with single interrupted sutures (Ethilon 5.0,
Johnson & Johnson Company, New Brunswick, NJ,
USA).)
Following defect closure, the randomization envelope
was opened and the patients were randomly distributed in
the test and control group. Patients in the test group
(DBBM/GTR+AB) were given postoperatively systemic
antibiotics, i.e., amoxicillin (Ospamox, Sandoz GmbH,
Kundl, Austria) starting the day of the surgery and followed
by 2 × 1 g/day for 7 days. No antibiotics were given for the
patients in the control group (DBBM/GTR). Since, in the
present study, no placebo was administered, the used drug
was not blinded. The antibiotics were given to the patients
in their original packages. Patients were randomly allocated
in the two different treatment groups. However, since no
placebo was used, the patients were aware of the allocated
treatment.
Clinical and radiographic measurements
All clinical measurements were made by the same blinded
(i.e., the examiner was not aware of the allocated treat-
ments) and calibrated examiner (ED) who was not the same
as the surgeon. Examiner calibration was performed as fol-
lows: five patients, not enrolled in the study, and showing at
least 4 teeth with probing depths ≥ 6 mm on at least one
aspect of each tooth, were evaluated by the examiner on 2
separate occasions, 48 h apart. Calibration was accepted if
measurements at baseline and at 48 h were similar to the
millimeter at ≥ 90%.
The following clinical parameters were measured at
baseline (i.e., before surgery) and at 12 months postopera-
tively: probing depth (PD), gingival recession (GR), and
clinical attachment level (CAL) using the same type of
periodontal probe (i.e., PCPUNC 15, Hu-Friedy, Chicago,
IL, USA).
Six points were probed at each tooth with the intrabony
defect—mesio-, mid-, disto-buccal and mesio-, mid-, disto-
lingual. The fixed reference point was cemento-enamel
junction (CEJ) or a filling’s margin if CEJ was not detect-
able. However, in the calculations, the same, at baseline, the
deepest site also exhibiting ≥ 6 mm was included.
Full mouth plaque scores (FMPS) [17] and full mouth
bleeding scores (FMBS) [18] were dichotomously calculated
as a percentage on the four surfaces of each tooth.
Intraoral radiographs (Planmeca Intra, serial no.:
ITH13227, tube type: D-0711SB, tube no.: 27899,
Planmeca, Helsinki, Finland) were taken in an analogue way
at baseline and at the 12-month evaluation. The radiographs
had the following settings for the different groups of teeth:
Exposition: maxillary incisors: 60 kV, 8 mA, 0.160 s/man-
dibular incisors: 60 kV, 8 mA, 0.125 s/maxillary premolars:
63 kV, 8 mA, 0.160 s/mandibular premolars: 63 kV, 8 mA,
0.125 s, maxillary molars: 63 kV, 8 mA, 0.2 s/mandibular
molars: 63 kV, 8 mA, 0.160 s.
To ensure accuracy, a long cone parallel technique
positioner was individually prepared for each of the includ-
ed patients. The used film was Dental Kodak Film
Carestream E-Speed Intraoral E-150 Adult Size 2 (31 mm ×
41mm) (Rochester, NY, USA). The machine used to de-
velop the films was Dürr Dental XR24 (Dürr Dental SE,
Fig. 1 Consort flowchart of the
study
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Bietigheim-Bissingen, Germany). Individual intraoral film
holder was made on the basis of RINN XCP® Holding
System (Densply RINN, York, USA). Following
manufacturing of individualized bite blocks for bite regis-
tration, a silicone impression mass was placed to the top
and bottom of the bite block (O-bite, DMG, Ridgefield
Park, NJ, USA). The silicone impression material was fixed
to the individualized bite blocks using acrylic glue
(Universal Tray Adhesive, Zhermack, Italy). Patients were
biting on the bite blocks with the impression mass while the
x-rays were made using the long cone parallel technique.
Subsequently, the positioner was disinfected and stored.
This procedure enabled to take the 1-year x-ray in the same
position as at baseline. To analyze the radiographs, a
negatoscope for viewing medical x-rays was used
(BakMed PF-622.4, BakMed, Łódź, Poland).
The following measurements were made on the intraoral
radiographs: defect depth (RxD) (i.e., the vertical distance
between the alveolar bone crest and the point on the root
where the width of periodontal ligament appeared to have a
physiologic appearance) and defect width (RxW) (i.e., the
horizontal space between the root surface and the most coro-
nal point of the bone crest). The measurements were made at a
2.5 magnification using a millimeter grid [19, 20].
Intrasurgical measurements
Intrasurgically the following measurements were made:
& Depth of the intrabony defect (DD) defined as the distance
from the most coronal point on the alveolar bone crest to
the most apical point of the intrabony defect
& Width of the intrabony defect (DW) defined as the dis-
tance from the most coronal point of the bone crest to the
root [21].
The defects were also classified according to the number of
walls as one-, two- or three-walled. If an increase in tooth
mobility (≥ grade 1) was detected after surgery, the tooth
was splinted. Figures 2 and 3 provide pertinent examples of
the treatment procedure.
Post-operative care
Starting with the day of the surgery, patients in the group
treated with GTR/DBBM+AB (i.e., test) group were given
1-g amoxycillin (Ospamox, Sandoz GmbH, Kundl,
Austria) twice daily for 7 days. Patients were instructed to
rinse with 0.2% chlorhexidine digluconate solution for a
Fig. 2 Representative bone defect treated with DBBM/GTR + AB (test
group). (a) Baseline clinical view, lower right first molar (46) presenting
with a pre-operative probing depth (PD) of 10mm. (b) Surgical view after
flap elevation and granulation tissue removal, intrasurgical probing of the
defect (INTRADD= 8mm). (c) Surgical view after filling the defect with
Cerabone® (botiss, biomaterials GmbH, Zossen, Germany) and covering
with trimmed collagen membrane (Collprotect®, botiss, biomaterials
GmbH, Zossen, Germany). (d) One year post-op clinical view, lower
right first molar presenting with a post-operative probing depth (PD) of
4 mm. (e) One year post-op minimally invasive reentry; view of the
buccal bone plate that has been restored. (f) Reentry; probing of the
residual defect INTRA DD= 2 mm (after granulation tissue removal).
(g) Baseline radiographic aspect of the intrabony defect distally to the
lower right first molar. (h) Radiographic result 1 year after treatment
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period of 2 weeks (Eludril, Pierre Fabre Laboratories, Paris,
France) twice a day. The sutures were removed 14 days
after surgery. After 2 weeks, patients resumed brushing at
the operated area using an ultrasoft post-surgical brush
(Elgydium, Pierre Fabre Laboratories, Paris, France).
During the 12-month observation period, patients were
recalled at 1, 2, 4 weeks, and 2, 3, 6, and 12 months post-
operatively to detect any potential infection/suppuration
and/or wound dehiscence during the early wound healing
phase. Additionally, the level of oral hygiene was moni-
tored and supragingival tooth cleaning was performed at
the treated sites. At 3, 6, and 12 months, FMPS and
FMBS scores were also recorded. Intraoral photographs
were taken at every visit.
Reentry procedure
Reentry procedure was performed at 1 year following regen-
erative surgery in those patients who have provided written
informed consent (i.e., 23 out of 41 patients). Following local
anesthesia, the mucoperiosteal flap was delicately elevated in
order to measure the residual defect depth and width.
Subsequently, the flap was repositioned and stabilized with
single interrupted sutures. A 0.2% chlorhexidine digluconate
solution (Eludril, Pierre Fabre Laboratories, Paris, France)
was prescribed for the next 2 weeks. Sutures were removed
at 7 days after reentry surgery.
Statistical analysis
Data analysis was made with a commercially available soft-
ware program (Statistica 13.1 software, Tulsa, USA). The
study was designed for testing superiority. The statistical unit
was the patient. The primary outcome variable was CAL gain
from baseline to 12 months. For these calculations, only the
same, at baseline the deepest site also exhibiting ≥ 6 mm, was
included. The values were expressed as the mean and standard
deviation. Comparisons within the groups were made with the
Wilcoxon matched pairs signed-rank test while between the
groups with the Mann-Withney rank-sum test. A p value of <
0.05 was considered as statistically significant.
Sample size was calculated a priori performing assumption
a standard deviation of CAL change 1 mm and to detect a
mean difference of 1 mm with a test power of 80% on 32
subjects. However, considering possible drop-outs, 41 pa-
tients were recruited and randomized to the study.
Results
Forty-one patients completed the study (27 women, 14 men;
mean age 41.78) (Table 1). Wound healing was generally
uneventful in both groups. Minimal (up to 2 mm) membrane
exposure was found in seven control and six test patients. No
signs of suppuration, extensive dehiscence, or swelling were
observed throughout the entire study period and none of the
Fig. 3 Representative bone defect treated with DBBM/GTR (control
group). (a) Baseline clinical view, lower left molar (36) presenting with
a pre-operative probing depth (PD) of 9 mm. (b) Surgical view after flap
elevation and granulation tissue removal, presenting with a intraoperative
probing of the defect INTRADD= 5mm. (c) Surgical view of the lingual
aspect of the bony defect. (d) Intrasurgical view of the defect filled with
Cerabone® (botiss, biomaterials GmbH, Zossen, Germany) and covered
with trimmed collagen membrane (Collprotect®, botiss, biomaterials
GmbH, Zossen, Germany). (e) Clinical view 1 year after treatment; a
post-operative probing depth (PD) of 4 mm. (f, g) One year post-op
minimally invasive reentry; complete filling of the defect with bonelike
tissue. (h) Reentry; probing of the residual defect INTRA DD= 3 mm
(after granulation tissue removal). (i) Baseline radiographic aspect of
intrabony defect mesially to the lower left first molar. (j) Radiographic
result 1 year after treatment
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patients reported intense pain, fever, or discomfort. Two pa-
tients from the test group reported hypersensitivity of the treat-
ed teeth while one patient from the control group reported a
cold sore confined to the corner of the mouth. All patients
maintained a good level of oral hygiene throughout the entire
study period, as evidenced through low FMPS and FMBS
scores (i.e., < 20%).
No statistically significant differences in terms of PD, GR,
CAL, and radiographic (RxD, RxW) parameters were found
at baseline between the 2 groups. At 1 year, both groups dem-
onstrated statistically significant improvements in terms of PD
reduction and CAL gain. Compared with baseline, GR in-
creased statistically significantly in the control group, but
not in the test group. In both groups, RxD and RxW improved
statistically significantly compared with baseline. Changes in
clinical and radiological parameters are shown in Table 2. No
statistically significant differences were found in any of the
investigated parameters between the two groups after 1 year.
The frequency distribution of CAL gain for both treatment
groups and number of residual pockets (PD˃5 mm) is shown
in Table 3. In the test group, 16 sites (76%) gained at least
3 mm of CAL. In the control group, no CAL gain occurred in
two sites (10%), whereas at ten sites (50%), the CAL gain was
2 mm. A CAL gain of 3 mm or more was measured in eight
defects (40%). In both groups, there were two residual pockets
(PD ˃ 5 mm) left.
Reentry surgery was performed in 23 out of the 41 patients
(i.e., in 11 patients from the test group and in 12 patients from
the control group, respectively). In both groups, a statistically
significant reduction of INTRA DD and INTRA DW was
measured compared with baseline, however without statisti-
cally significant differences between the groups (Table 4) .
Discussion
The present study has evaluated the potential effects of a post-
operative antibiotic regimen including the use of amoxicillin
on the outcomes of regenerative periodontal surgery using the
Table 2 Clinical recordings and
radiographic measurements in test
(GTR/DBBM+AB) and control
(GTR/DBBM) group at baseline
and 1 year post-op
Baseline (mean ± SD) 12 months (mean ± SD) p Diff ± SD
PD (mm)
Test 7.8 ± 1,5 4.0 ± 0.9 < 0.0001 3.8 ± 1.3
Control 7.4 ± 1,3 4.1 ± 1.3 < 0.001 3.3 ± 1.7
p = 0.8
GR (mm)
Test 0.9 ± 1,2 1.0 ± 1.2 p = 0.29(NS) − 0.2 ± 0.8
Control 1.2 ± 1,3 1.8 ± 1.6 < 0.05 − 0.6 ± 0.9
p = 0.1
CAL (mm)
Test 8.7 ± 1,4 5.0 ± 1.7 < 0.0001 3.6 ± 1.6
Control 8.6 ± 1,9 5.9 ± 1.6 < 0.001 2.7 ± 1.6
p = 0.07
RxD (mm)
Test 5.2 ± 2,1 2.0 ± 1.9 < 0.0001 3.2 ± 2.1
Control 4.8 ± 1,6 2.3 ± 1.2 < 0.001 2.5 ± 1.9
p = 0.3
RxW (mm)
Test 2.8 ± 0,9 1.6 ± 1.0 < 0.001 1.3 ± 0.9
Control 3.1 ± 0.7 2.0 ± 1.2 < 0.001 1.1 ± 1.0
p = 0.2
Table 1 Sample’s age/gender distribution and characteristics of respec-
tive intrabony defects
GTR/DBBM+AB (test) GTR/DBBM (control)
n 21 20
Sex 13F, 8M 14F, 6M
Mean age 44.67 ± 9.76 38.75 ± 8.27
Tooth position
Incisors 3 4
Canines 4 6
Premolars 10 5
Molars 4 5
Distribution and configuration of intrabony defects
1-wall 5 6
2-wall 12 9
3-wall 4 5
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combination of DBBM and GTR. At 12 months following
treatment, the results have failed to reveal statistically signif-
icant differences in any of the evaluated clinical parameters,
despite some minor improvements that were favoring the ad-
ditional use of systemic antibiotics. At 12 months following
therapy, mean CAL gain measured 3.6 ± 1.6 mm in the test
group with the corresponding value of 2.7 ± 1.6 mm in the
control one. These results are in line with those of previous
studies using a comparable regenerative approach and antibi-
otic protocol [22–24]. In those studies, the CAL gain mea-
sured 3.2 mm at 6 months [22], and 4.0 mm [23] and
3.9 mm [24], respectively. Interestingly, comparable results
were also obtained in other studies where DBBM and GTR
were used without postoperative administration of systemic
antibiotics (i.e., 4.1 mm by Sculean et al. [25] and 3.7 mm
by Iorio-Siciliano et al. [26]).
The rationale of using the combination of DBBM and GTR
is based on the findings from histologic studies from animal
models and human case reports/case series which have pro-
vided evidence for periodontal regeneration (i.e., formation of
cementum, periodontal ligament, and bone) following this
treatment modality [1, 27–29]. From a clinical point of view,
it is important to emphasize that substantial evidence from
randomized controlled clinical studies suggests that in
intrabony defects, regenerative periodontal surgery with
DBBM + GTR by means of collagen membranes may lead
to improved clinical outcomes in terms of CAL gain and PD
reduction compared with those achieved with open flap de-
bridement alone [10] and corroborate the previously men-
tioned histologic findings [1, 27–29].
Thus, taken together, the available histological and clinical
data suggest that the clinical improvements observed follow-
ing regenerative surgery with DBBM and GTRmay reflect, at
least to a certain extent, periodontal regeneration.
In the present study, both treatments resulted in statisti-
cally significant radiographic fill of the intrabony defects.
The mean RxD gain measured 3.2 ± 2.1 mm in the test
group and 2.5 ± 1.9 mm in the control one. This compares
well to the findings of other authors who have used a com-
parable regenerative approach [15]. In a study including a
total of 120 intrabony defects treated in 10 different re-
search centers, the radiographic resolution of the intrabony
component measured 3.2 mm in the DBBM + GTR group
[15]). However, when considering the value of an x-ray
examination, one should bear in mind the possibility of
some errors that may result from the difference in x-ray
projection. Although in the present study the best possible
attempts were made to standardize the x-rays by using a
stent to allow a similar positioning of the film for all exam-
ination time points, it cannot be excluded that some minor
differences between the x-ray projection occurred [7].
Therefore, the radiographic measurements should be
interpreted with caution and be always considered in the
light of the clinical outcomes.
In order to additionally verify the outcomes, a reentry
procedure was performed in 11 out of 21 defects of the test
group and in 12 out of 20 defects of the control group. The
measurements revealed that in the test group, mean INTRA
DD decreased from 5.5 ± 2.0 mm to 1.9 ± 0.9 mm (3.7 ±
1.8 mm INTRA DD gain), while the corresponding value
changed from 5.0 ± 1.6 mm to 2.3 ± 1.1 mm (2.7 ± 2.1 mm
Table 4 Clinical intraoperative
recordings in the test (GTR/
DBBM+AB) and control (GTR/
DBBM) group
Baseline (mean ± SD) 12 months (mean ± SD) p Diff± SD
Intra DD
Test (n = 11) 5.5 ± 2.0 1.9 ± 0.9 < 0.01 3.7 ± 1.8
Control (n = 12) 5.0 ± 1.6 2.3 ± 1.1 < 0.01 2.7 ± 2.1
p = 0.5
Intra DW
Test (n = 11) 3.7 ± 1.0 2.2 ± 1.3 < 0.05 1.5 ± 1.5
Control (n = 12) 3.8 ± 0.9 2.6 ± 1.3 < 0.05 1.1 ± 1.4
p = 1.0
Table 3 Varying levels of CAL
gain, bone gain, and number of
residual pockets PD > 5 mm at
1 year after treatment
GTR/DBBM+AB (test) GTR/DBBM (control)
CAL gain < 2 mm 1/21 2/20
4 mm ≤ CAL gain ≥ 2 mm 15/21 15/20
CAL gain > 4 mm 5/21 3/20
INTRA DD gain < 2 mm 1/11 4/12
INTRA DD loss 0/11 0/12
residual pockets PD > 5 mm 2/21 2/20
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INTRA DD gain) in the control group. None of the re-
entered defects showed bone loss, i.e., 91% of test and
67% of control defects showed at least 2-mm fill of the
intrabony component. Similar results following re-entry
were also reported by Camargo et al. (2000) (i.e., 3.7 to
3.8 mm of defect fill as measured from an acrylic stent)
[22]. When interpreting the value of re-entry procedures
after regenerative periodontal surgery, it is important to be
aware of the fact that such interventions are unable to pro-
vide evidence for periodontal regeneration (i.e., formation
of cementum, periodontal ligament, and bone) and may
thus only provide additional information to support the
clinical and radiographic findings [1, 2].
The potential additional benefit of using systemic antibi-
otics in conjunction with regenerative surgery has been inves-
tigated in previous studies using as regenerative material an
enamelmatrix derivative (EMD) alone or combinedwith bone
substitutes or membranes [13, 14, 30].
The rationale to select amoxicillin as antimicrobial agent
was based on the fact that it covers a wide variety of gram-
positive and gram-negative bacteria and is frequently used to
minimize postoperative complications following third molar
and implant surgeries [31, 32]. Since the aim of regenerative
periodontal surgery is not to treat bacterial caused periodontal
infection, but to reconstruct the defects left following nonsur-
gical anti-infective periodontal therapy, the postoperative ad-
ministration of antibiotics intends to prevent potential postop-
erative complications related to the insertion of foreign mate-
rials such as grafts and membranes [1, 2].
Sculean et al. [13] have treated 34 patients with one deep
intrabony defect by means of OFD and EMD followed by a
postoperative protocol with or without systemic antibiotics. In
that study, the antibiotic regimen consisted of a combination
of 3 × 375 mg amoxicillin and 3 × 250 mg metronidazole dai-
ly for 7 days. At 1 year following therapy, both treatments
resulted in statistically significant PD reduction and CAL gain
(i.e., in the EMD + AB group, mean PD decreased from 9.1 ±
1.5 mm to 4.5 ± 1.1 mm (p < 0.0001) and mean CAL changed
from 11.0 ± 1.6 mm to 7.5 ± 1.4 mm (p < 0.0001), while in the
EMD group, mean PD decreased from 9.0 ± 1.7 mm to 4.3 ±
1.7 mm (p < 0.0001) and the CAL changed from 10.6 ±
1.6 mm to 7.3 ± 1.5 mm (p < 0.0001). No statistically signifi-
cant differences were found in any of the investigated clinical
parameters between the 2 groups [13].
Comparable results were also reported by Röllke et al. and
Eickholz et al. [14, 30]. Following treatment of intrabony defects
with either EMD, EMD+ bone substitute or membrane. In that
study the postoperative regimen consisted of either 200-mg
doxycycline per day or placebo for a period of 7 days. The
clinical measurements at 6, and 12 or 24 months after regener-
ative surgery failed to reveal statistically significant differences
between the groups, thus questioning the clinical benefit of a
postoperative administration of systemic antibiotics following
regenerative periodontal surgery. Despite the fact that the bio-
materials used in the mentioned studies have either used EMD
alone or EMD and a bone grafting material without barrier
membranes, the findings are in line with those obtained in the
present study, thus questioning the routine administration of
systemic antibiotics following regenerative periodontal surgery,
provided that an optimal level of plaque control and mainte-
nance care is ensured [13, 14, 30].
An important aspect that needs to be carefully discussed
when interpreting the present results is the lack of placebo in
the control group. Since no placebo was given, the used drug
was not blinded and was given to the patients in the original
package. Therefore, the patients were aware of the allocated
treatment, which, obviously, is a shortcoming of the study.
The lack of a placebo may therefore explain, at least partly,
the tendency, though statistically not significant, for the im-
proved clinical outcomes in the test group compared with the
control one (i.e., 3.6 ± 1.6 mm CAL gain in the test vs. 2.7 ±
1.6 mm in the control group). On the other hand, the present
results compare well to the studies mentioned previously
where regenerative procedures were performed either with
[14, 30] or without the use of a placebo [13].
In the present study, we have tried to minimize the possi-
bility of bias by the fact that neither the examiner nor the
surgeon was aware of the treatment allocation (i.e., test or
control). All clinical measurements were made by the same
blinded (i.e. the examiner was not aware of the allocated treat-
ment groups) and calibrated examiner (ED), who was not the
same as the surgeon. Additionally, the surgical interventions
were scheduled in a way that the surgeon has only met the
patient immediately before regenerative surgery and at the
reentry surgery (in cases where re-entry was performed).
In conclusion, within their limits, the present results have
failed to show added clinical improvement following the ad-
ministration of systemic amoxicillin in conjunction with re-
generative periodontal surgery using DBBM and GTR.
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